Cytogen, Inc (217330) Fair Value & Analysis
Healthcare · KR · Market cap 96.4B KRW
Fair value as of: Jun 24, 2026
Analysis
Cytogen, Inc (217330) currently trades at 3,215 KRW, while our model-based Fair Value estimate is 2,775 KRW — implying the stock looks roughly 13.7% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Cytogen, Inc (217330) undervalued?
What is the fair value of 217330?
What is the quality score of 217330?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.